Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (6254)	1/14/1999 12:37:00 AM
From: Vector1	Read Replies (3) \| Respond to of 9719

Notes from HQ: ABSC Comfortable with in excess of $40m in rev in 99. Existing contracts cover the bulk of the estimate Expectation of the following additional deals in 99 -2 genomics deals -2 more sequencing deals -2 out licencing deals -2 additional integrated systems deals. First complete system delivered in Q3 This company has very elegant and powerful technology. Once they compete a system and the prove up the power of the system this company will rock. If they are able to meet their goals for the year as outlined above my price target for the stock is $20 by year end. Few people understand the power of ABSC's technology. They can potential increase screening speed 10 fold. The genomics revolution is producing hundreds of targets. These targets will need to be screened againt massive combinatorial libraries. High througput screening is the next bottleneck. ABSC has some of the answers. V1